Thyroid Cancer Research
After Rising for Decades, Thyroid Cancer Incidence StabilizesPosted: May 6, 2016
After rising steadily since the 1990s, the incidence of thyroid cancer in the United States may be leveling off, according to an analysis of data from NCI’s SEER program.
FDA Approves Lenvatinib for Radioactive Iodine-Refractory Thyroid CancerPosted: March 2, 2015
The FDA has approved lenvatinib (Lenvima) to treat some patients with the most common type of thyroid cancer.
TCGA study improves understanding of genetic drivers of thyroid cancerPosted: October 23, 2014
A comprehensive analysis of the genomes of nearly 500 papillary thyroid carcinomas (PTC) – the most common form of thyroid cancer – has provided new insights into the roles of frequently mutated cancer genes and other genomic alterations that drive disease development, information that may help improve diagnosis and treatment. Findings confirmed that PTCs are driven primarily by mutations in one of two cancer-associated genes: BRAF (and a particular BRAF mutation noted as V600E ) or RAS.
Sorafenib Improves Progression-Free Survival in Some Patients with Metastatic Thyroid CancerPosted: May 27, 2014
Results from an international phase III trial show that sorafenib (Nexavar®) may benefit patients with locally advanced or metastatic differentiated thyroid cancer that is no longer responding to treatment with radioactive iodine. Patients who were treated with sorafenib lived longer without their cancers getting worse than patients who received a placebo.
Low-Dose Radioactive Iodine Destroys Thyroid Tissue Left after SurgeryPosted: June 7, 2012
A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two European randomized controlled trials published May 3, 2012 in the New England Journal of Medicine.
Exploring the Anticancer Potential of Valproic Acid in Advanced Thyroid CancerPosted: March 7, 2012
In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks and then undergo a radioactive iodine uptake test.
Targeted Therapy Shows Benefit in Rare Type of Thyroid CancerPosted: December 2, 2011
Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.